Allyx Therapeutics was founded in 2018 as a spinout from Yale University and is focused on developing therapies for Alzheimer’s disease. Its lead candidate, ALX-001, is preparing to enter a pivotal Phase 2 clinical trial. The company has raised over $60 million in total funding following a recent $26.5 million financing. Allyx is noted as a Connecticut Innovations portfolio company. The recent capital raise is positioned to support the company’s near-term clinical program for ALX-001. Public commentary around the company emphasizes the high unmet need in dementia and Alzheimer’s among older adults.

Total raised

$37M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2026